leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid breytandi lyf - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
neotigason hart hylki 25 mg
teva b.v.* - acitretinum inn - hart hylki - 25 mg
neotigason hart hylki 10 mg
teva b.v.* - acitretinum inn - hart hylki - 10 mg
enalapril-hydrochlorthiazid krka tafla 20 mg /12,5 mg
krka sverige ab - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg /12,5 mg
losartan/hydrochlorothiazide medical valley (licolos plus) filmuhúðuð tafla 100/25 mg
medical valley invest ab - hydrochlorothiazidum inn; losartanum kalíum - filmuhúðuð tafla - 100/25 mg
taptiqom sine (taptiqom) augndropar, lausn 15 microg/ml + 5 mg/ml
santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml
losartan/hydrochlorothiazide medical valley (licolos plus) filmuhúðuð tafla 50/12,5 mg
medical valley invest ab - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50/12,5 mg
hydromed tafla 25 mg
medilink a/s - hydrochlorothiazidum inn - tafla - 25 mg
losartankalium/hydrochlorthiazid krka filmuhúðuð tafla 100 mg/12,5 mg
krka sverige ab - losartanum kalíum; hydrochlorothiazide - filmuhúðuð tafla - 100 mg/12,5 mg
diamox tafla 250 mg
amdipharm limited* - acetazolamidum inn - tafla - 250 mg